HRMY Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -15.94%, SMA50 -20.0%, SMA200 -14.8%). The stock’s 14-day RSI is 31.25 (weak momentum), while the ATR of 1.96 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -28.92% below its high and over 13.83% above its low. Average 10-day trading volume of 674.86 thousand shares is below the 3-month average of 848.34 thousand, indicating normal recent market interest.

Harmony Biosciences Holdings, Inc. has 57.53 million shares outstanding. The public float is 44.56 million shares, elevated short interest at 16.25% of float. This equals 4.27 million shares. The short ratio is 7.11 days. Institutional investors hold 117.35% of the float. Insiders own 11.69%. Valor IV Pharma Holdings, LLC holds 6.62 million shares, Marshman Fund Trust II has 6.05 million shares and Novo Holdings A/S has 4.41 million shares. Over the past six months, insider transactions show net selling. They sold 24.71 thousand shares across 2 transactions.

Wall Street analysts project EPS growth of 21.03% annually over the next five years. The latest quarter delivered EPS of $0.55. The next quarter is forecast at $0.82. Next year's EPS is expected at $50.00. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 10 Buy ratings, 4 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $55.00 to $29.00. The high target offers 54.76% upside. The low target suggests -18.4% downside. The mean target is $43.22. This offers 21.61% upside. Harmony Biosciences Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by -27.63%. The prior quarter beat by -54.76%. Over the last six quarters, Apple has recorded several small beats. These include 14.86% in February 25, 2025.

Harmony Biosciences Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $78.25. This means the shares are trading below this model’s fair value.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) closed at $35.54 USD, losing -$1.30 (-3.53%) from the previous close of $36.84. The stock is currently mid-range between its 52-week high and low $25.52 and $40.87. With a market capitalization of about $2.06 billion, Harmony Biosciences Holdings, Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.94). Key stats such as the average daily volume over the past year has been around 851.12 thousand shares, in line with its 52-week average. Headquartered in Plymouth Meeting, PA, Harmony Biosciences Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jeffrey Dayno, the company employs approximately 293 people and listed since August 19, 2020. Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions.

Harmony Biosciences Holdings, Inc. trades at a P/E ratio of 14.15, slightly below the S&P 500 average, with a price-to-sales ratio of 2.3 and a price-to-book ratio of 2.27 suggesting the stock is closer to book value. The P/FCF stands at 6.04, also above market averages.

Our AI price prediction model suggests that Harmony Biosciences Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.02%, with price expected at $39.10 by July 27, 2026, within a range of $38.24 to $40.01 3-Month Outlook: Projected fall of -5.18%, reaching $33.70 by October 09, 2026, with a range of $31.17 to $35.97. 1-Year Outlook: Projected gain of 2.42%, with price at $36.40 by July 13, 2027, within a range of $35.21 to $37.85.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) shares are flat -4.04% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Harmony Biosciences Holdings, Inc. trading at a premium to the broader market with a P/E of 14.15. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $54.26, suggesting 52.67% upside. Our AI forecast model points to short-term strength (10.02% over two weeks), a medium-term fall (-5.18% over three months), and a longer-term gain (2.42% over one year), with expected trading ranges indicating moderate volatility.